Cargando…
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour growth in BRCA1/2 wild-type TNBC preclinical models. The PAR...
Autores principales: | Teo, Zhi Ling, O’Connor, Mark J., Versaci, Stephanie, Clarke, Kylie A., Brown, Emmaline R., Percy, Luke W., Kuykhoven, Keilly, Mintoff, Christopher P., Savas, Peter, Virassamy, Balaji, Luen, Stephen J., Byrne, Ann, Sant, Sneha, Lindeman, Geoffrey J., Darcy, Phillip K., Loi, Sherene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427618/ https://www.ncbi.nlm.nih.gov/pubmed/37582853 http://dx.doi.org/10.1038/s41523-023-00568-5 |
Ejemplares similares
-
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
por: Wein, Lironne, et al.
Publicado: (2017) -
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2020) -
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2022) -
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2017) -
Checkpoint blockade in the treatment of breast cancer: current status and future directions
por: Wein, Lironne, et al.
Publicado: (2018)